share_log

JP Morgan Downgrades Vir Biotechnology to Neutral, Lowers Price Target to $9

Benzinga ·  Jan 29 06:06

JP Morgan analyst Eric Joseph downgrades Vir Biotechnology (NASDAQ:VIR) from Overweight to Neutral and lowers the price target from $23 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment